ras mutation and platinum resistance in human ovarian carcinomas in vitro

International Journal of Cancer

Volumn 77, Issue 1, 1998, Pages 94-100

  Holford, Jeffrey ^a   Rogers, Paul ^a   Kelland, Lloyd R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PLATINUM;

AMINO ACID SEQUENCE; ARTICLE; CELL CULTURE; DNA SEQUENCE; ENZYME PHOSPHORYLATION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; ONCOGENE RAS; OVARY CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR RESISTANCE;

CARCINOMA; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, RAS; HUMANS; MUTATION; OVARIAN NEOPLASMS; PLATINUM; TUMOR CELLS, CULTURED;

EID: 0032479412     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980703)77:1<94::AID-IJC15>3.0.CO;2-9     Document Type: Article

References (21)

1. ARENDS, M.J., MCGREGOR, A.M., TOFT, N.J., BROWN, E.J.H. and WYLLIE, A.H., Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availability. Brit. J. Cancer, 68, 1127-1133 (1993).
2. BASU, A. and CLINE, J.S., Oncogenic transformation alters cisplatin-induced apoptosis in rat embryo fibroblasts. Int. J. Cancer, 63, 597-603 (1995).
3. BEALE, P., JONES, M., VALENTI, M., SHARP, S.Y. and KELLAND, L.R., BCL-2 expression in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines and companion xenografts. Brit. J. Cancer, 73 (Suppl. 16), 19 (1996).
4. ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Oncogene, 11, 1487-1498 (1995).
5. CHEN, C.Y. and FALLER, D.V., Phosphorylation of Bcl-2 protein and association with p21Ras in Ras-induced apoptosis. J. biol. Chem., 271, 2376-2379 (1996).
6. CMIEN, C.H. and CHOW, S.N., Point mutation of the ras oncogene in human ovarian cancer. DNA Cell Biol., 12, 623-627 (1993).
7. GRIMALDI, K.A., MCADAM, S.R., SOUHAMI, R.L. and HARTLEY, J.A., DNA damage by anti-cancer agents resolved at the nucleotide level of a single copy gene: evidence for a novel binding site for cisplatin in cells. Nucl. Acids Res., 22, 2311-2317 (1994).
8. HOLFORD, J., SHARP, S.Y., MURRER, B.A., ABRAMS, M. and KELLAND, L.R., In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Brit. J. Cancer, 77, 366-373 (1998).
9. ISHONISHI, S., HOM. D.K., THIEBAUT, F.B., MANN, S.C., ANDREWS, P.A., BASU, A., LAZO, J.S., EASTMAN, A. and HOWELL, S.B., Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res., 51, 5903-5909 (1991).
10. JANSEN, B., SCHLAGBAUER-WADL, H., EICHLER, H.G., WOLFF, K., VAN ELSAS, A., SCHRIER, P.I. and PEHAMBBRGER, H., Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis. Cancer Res., 57, 362-365 (1997).
11. MARAIS, R., SPOONER, R.A., LIGHT, Y., MARTIN, J. and SPRINGER, C.J., Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res., 56, 4735-4742 (1996).
12. MELLISH, K.J. and KELLAND, L.R., Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine dichloro eyclohexylamine platinum (IV) (JM216) in two human ovarian carcinoma cell lines. Cancer Res., 54, 6194-6200 (1994).
13. OSMAK, M., BEKETIC-ORESKOVIC, L., MATULIC, M. and SORIC, J., Resistance of human larynx carcinoma cells to cisplatin, gamma-irradiation and methotrexate does not involve overexpression of c-myc or c-Ki-ras oncogenes. Mutation Res., 303, 113-120 (1993).
14. PEREZ, R.P., GODWIN, A.K., HANDEL, L.M. and HAMILTON, T.C., A comparison of clonogenic, microtetrazolium and sulphorhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Europ. J. Cancer. 29A, 395-399 (1993a).
15. FEREZ, R.P., HAMAOUCHI, K., TRACEY, P.A., HANDEL, L.M., HAMILTON, T.C. and GODWIN, A.K., Transformation of rat ovarian epithelial and Rat-1 fibroblast cell lines by RAST24 does not influence cisplatin sensitivity. Cancer Res., 53, 3771-3775 (1993b).
16. PILLAIRE, M.J., MARGOT, A., VILLANI, G., SARASIN, A., DEFAIS, M. and GENTIL, A., Mutagenesis in monkey cells of a vector containing a single d(GpG) cis-diamminedichloroplatinum (II) adduct placed on codon 12 of the human H-ras proto-oncogene. Nucl. Acids Res., 22, 2519-2524 (1994).
17. +-ATPase activity and cisplatin sensitivity between transformants induced by H-ras and those induced by K-ras. Int. J. Cancer, 58, 672-677 (1994).
18. SKLAR, M.D., Increased resistance to cis-diamminedichloroplatinum (IT) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res., 48, 793-797 (1988).
19. SMIT, V.T., BOOT, A.J., SMITS, A.M., FLEUREN, G.J., CORNELISSE, C.J. and BOS, J.L., K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucl Acids Res., 16, 7773-7782 (1988).
20. VAN'T VEER, L.J., HERMENS, R., VAN DEN BERG-BAKKER, L.A.M., CHENG, N.C., FLEUREN, G.J., Bos, J.L., CLETON, F.J. and SCHRIER, P.I., ras oncogene activation in human ovarian carcinoma. Oncogene, 2, 157-165 (1988).
21. WALTON, M.I., WU, E., KOSHY, P., SHARP, S.Y. and KELLAND, L.R., p53 status and CDDP sensitivity in a panel of ovarian cancer cell lines. Proc. Amer. Assoc. Cancer Res., 37, abstract 2747 (1996).